Quantum Immunologics, Inc. Announces Appointment of Wilhelmina Tribble to Board

Quantum Immunologics, Inc. Announces Appointment of Wilhelmina Tribble to Board


TAMPA, FL--(Marketwire - August 05, 2010) - Quantum Immunologics, Inc. (QI or Company), a privately owned biotech company focused on cancer research, announced today that its independent directors selected Wilhelmina Tribble of Orlando, FL to join the Board as the sixth independent board member. Charles "Chuck" Broes, the CEO, appointed Ms. Tribble to the Board effective July 21, 2010 for a term expiring on December 31, 2010 or until the next election of the board, whichever occurs last.

Quantum Immunologics is dedicated to the research, development and production of products and services that will promote unique, individualized immunologic cancer treatment and early detection technologies.

Chuck Broes stated: "Wilhelmina is a welcome and valuable addition to our Board. Further, I requested that Wilhelmina assist the Company in adopting a Diversity Plan for the Company. The appointment of Wilhelmina Tribble as the sixth independent board member is in accordance with the mission of the Company to adhere to the highest standards of corporate governance and transparency to our shareholders."

Ms. Tribble is the founder and President of LTA, Inc., providing training, consulting and H.R. development services. Since 1985, Wilhelmina Tribble and her associates have challenged, inspired and trained a diverse and far ranging group of clients in over 40 countries around the world, from Australia to Argentina.

Ms. Tribble has served the Florida legal community as a layperson for over 20 years. She says this is her "community service" work. She began by serving on Florida Bar grievance committees in Miami. The Florida Supreme Court appointed her, the first layperson, to The Florida Bar Board of Governors and served for two terms. She was also appointed to serve on the Florida Supreme Court Commission on Professionalism and the Standing Committee on Fairness and Diversity in the Courts, where she is actively helping to further the cause of professionalism and inclusion in the legal profession throughout the state of Florida.

As a member of the diversity subcommittee, she wrote "Successful Lawyering in a Diverse Society," a four-hour diversity workshop that is certified for CLE credit. She facilitates the workshop for Florida law firms, law schools and bar associations. Wilhelmina also trains attorneys, judges and bar staff to facilitate the course for the Florida Bar.

As a consultant, Ms. Tribble works closely with and guides law firms and companies through the lengthy and sometimes complex process of a Diversity Initiative. In part, she helps them attract and retain diverse employees, educate the workforce on diversity issues and examine policies which may be blocking their goals.

Wilhelmina Tribble is a native New Yorker who has lived on both the East and West coasts and even in between... Chicago. She is a mother, an avid (wanna be) golfer and spends much of her spare time learning and relearning the game. She is also a tennis player, snow skier and a bowler. Orlando is home for Wilhelmina now where she continues to develop long lasting personal and business relationships.

Ms. Tribble has a Bachelor of Science degree in Education from the City University of New York and her Master's in Education Administration from California State University. In addition she has several certifications in several areas of human resources development.

About Quantum Immunologics
Quantum Immunologics is dedicated to the research, development and production of products and services that will promote unique, individualized immunologic cancer treatment and early detection technologies with a high rate of efficacy, minimal side effects and greatly reduced cost compared to current treatments.

Quantum Immunologics has received FDA authorization to apply its exclusively licensed patented immunotherapy in a Phase I/II human clinical study. QI's Phase I/II clinical trial, which involves a cohort of 27 patients with advanced-stage metastatic breast cancer, is designed around the use of QI's proprietary dendritic cell therapy, which employs oncofetal antigen ("OFA") to recruit the patient's own immune system to target and combat the cancer cells with the intent to improve patient survivability and quality of life.

Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include, but are not limited to, statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Quantum Immunologics, Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.